ReNeuron Group Plc said that it has been granted a US patent for the technology underpinning its candidate stem cell therapy for type 1 diabetes. The patent, CD56 Positive Human Adult Pancreatic Endocrine Progenitor Cells, contains broad claims relating to methods for culturing and identifying living islet progenitor cells by way of the expression of the CD56 cell surface marker.
